NCT07208305View on ClinicalTrials.gov

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

PHASE3RecruitingINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
NauseaVomiting
Interventions
DRUG

Olanzapine

Oral olanzapine (2.5mg per night, oral, 30 minutes before taking opioids on the first day of treatment), for 7 consecutive days.

DRUG

Metoclopramide

Metoclopramide (10mg/ time, orally, 3 times a day) was taken orally for 7 days.

Trial Locations (1)

810000

RECRUITING

Qinghai University Affiliated Hospital, Xining

All Listed Sponsors
lead

Affiliated Hospital of Qinghai University

OTHER

NCT07208305 - Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting | Biotech Hunter | Biotech Hunter